Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Both the FDA and Novo Nordisk are advising patients and providers to check their supplies of Ozempic for counterfeit product. Individuals in possession of a counterfeit product are urged to call Novo ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

Ozempic, originally prescribed for type 2 diabetes, is now widely used off-label for weight loss, but rapid results can lead ...

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...